(Q34443415)

2 August 2017

1 reference

title

Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside (English)

1 reference

2 August 2017

1 reference

Rodvold KA

1

1 reference

PubMed ID

11714223

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

21

1 reference

2 August 2017

11 Pt 2

1 reference

2 August 2017

319S-330S

1 reference

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

2 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

The future--can we learn from the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Penicillin dosing for pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacodynamics of fluoroquinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Application of fluoroquinolone pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacodynamics and pharmacokinetics of levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Clinical pharmacokinetics of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

The selection of appropriate dosages for intravenous ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Antipyretic Therapy's future

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

21 January 2018

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

Pharmacokinetics and pharmacodynamics of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.319S.33904

10.1592/PHCO.21.18.319S.33904

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11714223